These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, Schnorr D, Loening SA, Jung K. Cancer; 2005 Sep 01; 104(5):993-1003. PubMed ID: 16007682 [Abstract] [Full Text] [Related]
10. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. Ulmert D, Serio AM, O'Brien MF, Becker C, Eastham JA, Scardino PT, Björk T, Berglund G, Vickers AJ, Lilja H. J Clin Oncol; 2008 Feb 20; 26(6):835-41. PubMed ID: 18281654 [Abstract] [Full Text] [Related]
11. [Measurement and analysis of different serum PSA in patients with benign prostatic hyperplasia]. Li Y, Xu P, Zhang PA, Su HW, Zhang J. Zhonghua Nan Ke Xue; 2003 Aug 20; 9(5):361-3, 366. PubMed ID: 14513646 [Abstract] [Full Text] [Related]
15. Integrated microfluidic systems with an immunosensor modified with carbon nanotubes for detection of prostate specific antigen (PSA) in human serum samples. Panini NV, Messina GA, Salinas E, Fernández H, Raba J. Biosens Bioelectron; 2008 Feb 28; 23(7):1145-51. PubMed ID: 18162392 [Abstract] [Full Text] [Related]
18. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia]. Gao ZW, Liu G, Sheng BW. Ai Zheng; 2004 Jun 28; 23(6):701-3. PubMed ID: 15191675 [Abstract] [Full Text] [Related]